Blog

Designing better medicines using AI and big data

By its own definition, South By Southwest dedicates itself to helping creatives achieve their goals, and proves that the most unexpected discoveries happen when diverse topics and people come together.

And this is what brought our Benevolent Team to Texas - to share our collective vision of using the power of technology to solve something that truly matters to the world. For us this means tackling the most challenging and devastating diseases that currently have no cure, and we believe our efforts can and will change outcomes for patients.

In this video live from SXSW last month, our team of scientists and AI experts presented a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

At SXSW we used the example of Glioblastoma Multiforme, a very aggressive, currently incurable and most common form of brain cancer. We demonstrated something different and a little unconventional - the creative approach of how our team of BenevolentAI scientists, AI experts, engineers and chemists come together to try and solve such a complicated disease.

AI helps us uncover relationships between diseases and symptoms, drugs and their effect, the patients who respond to treatments and so much more. Relationships that would previously not have been uncovered due to the overwhelming volume of biomedical information and the inherent complexity of biology, diseases and the human body.

It’s too early to say if there will be an effective treatment for Glioblastoma any time soon. But every day, we improve our platform and increase the likelihood of finding a treatment. And we hope to return to SXSW to demonstrate the progress we are making on this devastating disease.

More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021